(Q44404528)

2 December 2017

Economic evaluation of orlistat in overweight and obese patients with type 2 diabetes mellitus (English)

1 reference

2 December 2017

Economic Evaluation of Orlistat in Overweight and Obese Patients with Type 2 Diabetes Mellitus (English)

1 reference

Crossref

DOI

https://api.crossref.org/works/10.2165/00019053-200321070-00005

24 December 2023

0 references

1 reference

1 reference

https://api.crossref.org/works/10.2165/00019053-200321070-00005

24 December 2023

1 reference

https://api.crossref.org/works/10.2165/00019053-200321070-00005

24 December 2023

author name string

Andreas Maetzel

1

1 reference

2 December 2017

Jörg Ruof

2

1 reference

2 December 2017

Melva Covington

3

1 reference

2 December 2017

Anne Wolf

4

1 reference

2 December 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12696990

24 December 2023

publication date

1 January 2003

1 reference

2 December 2017

1 reference

2 December 2017

21

1 reference

2 December 2017

501-512

1 reference

2 December 2017

7

1 reference

https://scigraph.springernature.com/pub.10.2165/00019053-200321070-00005

2 December 2017

0 references

cites work

Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial

1 reference

12 December 2020

Glycaemia and vascular effects of type 2 diabetes. UKPDS is not a cohort study and analysis is misleading

1 reference

12 December 2020

A health economic model to assess the long-term effects and cost-effectiveness of orlistat in obese type 2 diabetic patients

1 reference

12 December 2020

Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994.

1 reference

12 December 2020

Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin

1 reference

12 December 2020

Long-term effects of modest weight loss in type II diabetic patients.

1 reference

12 December 2020

Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial

1 reference

12 December 2020

Reducing the cost of frequent hospital admissions for congestive heart failure: a randomized trial of a home telecare intervention

1 reference

12 December 2020

Representing uncertainty: the role of cost-effectiveness acceptability curves.

1 reference

12 December 2020

Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study.

1 reference

12 December 2020

Weight gain as a risk factor for clinical diabetes mellitus in women.

1 reference

12 December 2020

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

1 reference

12 December 2020

Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41). United Kingdom Prospective Diabetes Study Group.

1 reference

12 December 2020

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

12 December 2020

The effects of improved glycemic control on complications in type 2 diabetes

1 reference

12 December 2020

The cost of obesity: the Australian perspective

1 reference

12 December 2020

The burden of chronic hyperglycemia

1 reference

12 December 2020

A prospective study of weight change and health-related quality of life in women.

1 reference

12 December 2020

Impact of obesity on health-related quality of life in patients with chronic illness

1 reference

12 December 2020

Standards of medical care for patients with diabetes mellitus

1 reference

12 December 2020

Seeing what you want to see in randomised controlled trials: versions and perversions of UKPDS data. United Kingdom prospective diabetes study

1 reference

12 December 2020

The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56).

1 reference

12 December 2020

Economic consequences of diabetes mellitus in the U.S. in 1997. American Diabetes Association

1 reference

12 December 2020

Four costliest outpatient procedures

1 reference

12 December 2020

The economic cost of obesity: the French situation

1 reference

12 December 2020

Markov models in medical decision making: a practical guide.

1 reference

12 December 2020

Diabetes Intervention Study. Multi-intervention trial in newly diagnosed NIDDM.

1 reference

12 December 2020

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

1 reference

12 December 2020

Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group.

1 reference

12 December 2020

Obesity and physical and emotional well-being: associations between body mass index, chronic illness, and the physical and mental components of the SF-36 questionnaire.

1 reference

12 December 2020

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

1 reference

12 December 2020

The progressive cost of complications in type 2 diabetes mellitus

1 reference

12 December 2020

Orlistat: selective inhibition of caloric absorption can affect long-term body weight

1 reference

12 December 2020

Economic assessment of troglitazone as an adjunct to sulfonylurea therapy in the treatment of type 2 diabetes.

1 reference

12 December 2020

The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized, placebo-controlled trial

1 reference

12 December 2020

Pharmacologic therapy for type 2 diabetes mellitus

1 reference

12 December 2020

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

1 reference

12 December 2020

Direct medical costs of complications resulting from type 2 diabetes in the U.S.

1 reference

12 December 2020

1 reference

12 December 2020

Orlistat inhibits dietary cholesterol absorption

1 reference

12 December 2020

The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study

1 reference

12 December 2020

1 reference

12 December 2020

Impairment of health and quality of life using new US federal guidelines for the identification of obesity.

1 reference

12 December 2020

International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity

6

19

788

Levy

1995

1 reference

Crossref

DOI

https://api.crossref.org/works/10.2165/00019053-200321070-00005

24 December 2023

Identifiers

DOI

1 reference

Dimensions Publication ID

2 December 2017

0 references

1 reference